BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.26), $0.13 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $279.9 million versus the consensus estimate of $289.44 million.
Updated 2016 Financial Guidance
Revenue Guidance ($ in millions)
| Item | ||||
| Provided August 4, 2016 | Updated October 27, 2016 | |||
| Total BioMarin Revenues | $1,100 to $1,150 | Unchanged | ||
| Vimizim Net Product Revenues | $340 to $360 | Unchanged | ||
| Naglazyme Net Product Revenues | $290 to $320 | Unchanged | ||
| Kuvan Net Product Revenues | $340 to $360 | Unchanged |
Select Income Statement Guidance ($ in millions, except percentages)
| Item | ||||
| Provided August 4, 2016 | Updated October 27, 2016 | |||
| Cost of Sales (% of Total BioMarin Revenues) | 18.0% to 19.0% | Unchanged | ||
| Selling, General and Admin. Expense | $470 to $490 | $460 to $480 | ||
| Research and Development Expense | $670 to $690 | $650 to $670 | ||
| GAAP Net Loss | $(620) to $(650) | $(600) to $(630) | ||
| non-GAAP Loss | $(30) to $(50) | $(10) to $(30) |
Recent Key Program Updates
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.